Gal-9, sTIM-3, and FABP1 were further significantly higher in RA patients with moderate-to-severe NAFLD than in those with none-to-mild NAFLD. The gene discussed is LGALS9; the disease is metabolic dysfunction-associated steatotic liver disease.